Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

Key facts

Sponsor

Harmony Biosciences Management, Inc.

Principal Investigator

Kristen Bzdek, MD

Harmony Biosciences Management, Inc.

Intervention

ZYN002(drug)

Enrollment

20 enrolled

Eligibility

4-17 years · All sexes

Timeline

2020 – 2022

Study locations (3)

• Greenwood Genetic Center, Greenville, South Carolina, United States
• Lady Cilento Children's Hospital - South Brisbane, Brisbane, Queensland, Australia
• Genetics Clinics Australia, Melbourne, Victoria, Australia

Collaborators

Zynerba Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for 22q11.2 deletion syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05664412
  Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome
  Stephan Eliez
• RECRUITINGNCT05924347
  Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
  UMC Utrecht
• RECRUITINGNCT05329935
  Congenital Athymia Patient Registry
  Sumitomo Pharma Switzerland GmbH
• RECRUITINGNANCT04639388
  Understanding of Psychotic Disorders in Children With 22q11.2DS
  Hôpital le Vinatier
• RECRUITINGNCT00556530
  Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
  Albert Einstein College of Medicine

See all trials for 22q11.2 deletion syndrome →